CRMD News and Press, CorMedix Inc. From 07/06/22

SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in shares of the CorMedix Inc. (NASDAQ: CRMD). Investors, who purchased shares of CorMedix Inc. (NASDAQ: CRMD) prior to July 2020 and c...

Gainers: Calithera Biosciences (CALA) +4%. Allakos (ALLK) +3%. CorMedix (CRMD) +2%. Core Scientific (CORZ) +2%. Greenidge Generation Holdings (GREE) +2%. Losers: CalAmp (CAMP) -15%. LendingTree (TREE) -14%. The RealReal (REAL) -8%. Ikena Oncology (IKNA) -6%. Rain Therapeutics (RAIN)...

BERKELEY HEIGHTS, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will be...

Image source: The Motley Fool. CorMedix Inc Common Stock (NASDAQ: CRMD) Q1 2022 Earnings Call May 12, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: CorMedix Inc Common Stock (CRMD) Q1 2022 Earnings Call Transcript...

CorMedix Inc. (CRMD) Q1 2022 Earnings Conference Call May 12, 2022 16:30 ET Company Participants Daniel Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Erin Mistry - Senior Vice President and Head, Payer Strate...

CorMedix press release (NASDAQ:CRMD): Q1 GAAP EPS of -$0.18 beats by $0.04. Revenue of $0.01M (-88.9% Y/Y) misses by $0.01M. Joe Todisco, CorMedix CEO, commented, “We are very pleased to share the updates this week regarding the business and plans for commercialization. If approved by ...

BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for th...

CorMedix (NASDAQ:CRMD) hired Joe Todisco as its new CEO, effective May 10. The infectious and inflammatory diseases developer also said that Chief Commercial Officer Tom Nusbickel has left. Donna Ucci joined the Company as SVP and head of global quality. Liz Hurlburt, EVP ...

BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates regarding its le...

AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...